Aptinyx to Present Data for NYX-2925 at the 6th International Congress on Neuropathic Pain

Evanston, Ill., June 14, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that it will present a poster on its lead product, NYX-2925, at the 6th International Congress on Neuropathic Pain, held in Gothenburg, Sweden from June 15-18, 2017.

"Results from this study demonstrate that NYX-2925 has therapeutic potential in neuropathic pain with both rapid-acting and durable effect," said Joseph Moskal, Ph.D., chief scientific officer of Aptinyx. "We look forward to sharing additional findings at scientific and medical meetings as we advance NYX-2925 through Phase 2 clinical studies for the treatment of pain associated with painful diabetic neuropathy."

Title: The NMDA receptor modulator NYX-2925 shows therapeutic potential in preclinical models for the treatment of neuropathic pain

- **Presenter:** Dr. Torsten M. Madsen, M.D., Ph.D., Chief Medical Officer of Aptinyx
- **Presentation Date & Time:** June 17, 2017 from 12:30-2:00pm CET
- **Summary:** The analgesic effect of NYX-2925 was evaluated in rat models of neuropathic pain, demonstrating daily oral administrations for 14 days resulted in significant efficacy over vehicle that was sustained throughout the dosing period.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism of modulating NMDA receptors, resulting in drugs that are both highly effective and well tolerated. The company's lead drug candidate, NYX-2925, is in Phase 2 clinical development as a therapy for neuropathic pain, an area of significant unmet need. Aptinyx's proprietary chemistry platform has yielded a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat a number of disorders of the brain and nervous system. For more information, visit www.aptinyx.com.

# # # #

Company Contact:
Ashish Khanna
Chief Business Officer
Aptinyx Inc.
corporate@aptinyx.com

847-871-0377

Media Contact:
Ian Stone
Canale Communications
ian@canalecomm.com
619-849-5388